logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Venous Thromboembolism

    FiltersReset Filters
    3 results

    • fragmin

      (Dalteparin Sodium)
      Pfizer Laboratories Div Pfizer Inc
      Usage: FRAGMIN is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, deep vein thrombosis (DVT) prevention in surgical and at-risk patients, extended treatment of symptomatic VTE in cancer patients, and VTE treatment in pediatric patients. It is not for acute VTE treatment.

    • pradaxa

      (dabigatran etexilate mesylate)
      Boehringer Ingelheim Pharmaceuticals Inc.
      Usage: PRADAXA Capsules are indicated for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism in adults, prophylaxis post-hip replacement surgery, and treating and preventing venous thromboembolic events in pediatric patients aged 8 to less than 18 years.

    • xarelto

      (rivaroxaban)
      Janssen Pharmaceuticals, Inc.
      Usage: XARELTO is indicated for reducing stroke and systemic embolism in nonvalvular atrial fibrillation, treating deep vein thrombosis and pulmonary embolism, preventing recurrence of these conditions, and offering prophylaxis in post-surgery and hospitalized patients. It also reduces major cardiovascular events in patients with coronary artery disease and peripheral artery disease.